Japan has taken significant steps in establishing itself as a major player in the global clinical research community, driving the demand for more clinical trials across East Asia as a result. By officially acknowledging and seeking clinical data from the Asia Pacific region, Japan is facilitating a dialogue with one of the most powerful and capable clinical trial landscapes in the world: South Korea.
On the heels of our recent post on our presence at this week’s DIA Japan 2015, BBK welcomes Philip Gregory, the General Manager of George Clinical - CRO China as our guest contributor. With more than 20 years of experience in pharmaceutical, biotech and medical device marketing, Mr. Gregory has spent over 14 years supporting the expansion of clinical trial capabilities in Asia. He will be providing his insights over the course of a three-part blog series on the growth of clinical research across the Asia Pacific region.
We are very excited to be attending next week’s 12th Annual Meeting DIA Japan 2015, to be held at Tokyo Big Sight in Tokyo, November 15 – 17. It’s the first time that many of us based here in our U.S. headquarters will be joining our Japan team since opening our new Tokyo office over the summer. Under the theme “Medicine Development” this year’s event is set to focus on the innovative and constructive influence of patients on the enterprise of clinical R&D – a topic that’s always at the center of our work here at BBK.
Choosing the right countries and sites for a particular study remains one of the industry’s biggest challenges – but it doesn’t have to be. When the time comes to select sites for your clinical research study, there are many considerations that can guide your decisions to ensure the best possible outcome.
Topics: Site Selection
A recent survey conducted on behalf of the National Institute for Health Research Clinical Research Network shows that 89% of people would be willing to take part in a clinical trial if they were diagnosed with a medical condition or disease. This figure has very positive implications for the enterprise of global clinical research, as patient enrollment is one of the defining aspects of its success. So why is it that half of all investigative sites under-enroll for patients, and 11% of sites fail to enroll a single patient for a clinical trial?
It’s award season, and we’re proud to announce a few new wins including an Rx Club Award and three American Graphic Design Awards, all for Creative Excellence. Congrats to our marketing and creative teams!
There are many variables to consider when creating an advertising campaign for your clinical research study, but among the most important is the decision of which mediums to deploy. It can be staggering to think about all of the ways in which your potential patients might learn about your clinical research opportunity, and deciding how to make your campaign most visible can be challenging.
Following an inspiring few days at last week’s SYNERGY conference in Boston, hosted by ACRES, we’re in London at the Allan Lloyds 9th Annual Optimizing Clinical Research Summit this week to share ideas with colleagues and speak about mHealth and patient engagement.
October 1, 2015 marks an important milestone for anyone using or accepting cards in the United States. Known as the EMV liability shift (EMV is an acronym for Europay, MasterCard, Visa), it’s a deadline that’s fueling the replacement of magnetic stripe cards for more secure, globally accepted smart chip cards in the U.S. by shifting the liability for fraudulent transactions from financial institutions to the merchants that continue to accept them. So what does all this mean for global study patient reimbursement programs?
In today’s competitive clinical study landscape, ensuring that your study stands out has never been more important. Communicating the right information with your target audience, and understanding how they ingest this information, is a major factor in building a successful recruitment campaign. That is why it is crucial that your campaign is culturally adapted— to ensure that it resonates with audiences in all countries and cultures.